Keynote speaker
Chief Scientific Officer, Vertero Therapeutics
Becca Senter, Chief Scientific Officer at Vertero Therapeutics, gave a keynote at 10th MASH Drug Development Summit 2026 (Boston, United States of America, 15–17 Sept 2026) in the session “Targeting Bile Salt Hydrolase with the Oral Small Molecule VT-6382 as a Novel and Differentiated Approach to Treating MASH and Liver Fibrosis”.
15–17 Sept 2026Boston, United States of America
Director, Madrigal Pharmaceuticals
Senior Director, Cellarity
Chief Executive Officer, Cirius Therapeutics
Faculty, Harvard Medical School and Mass General Brigham
Associate Director, Clinical Research, Akero Therapeutics
Vice President, Discovery Biology, Sepia Therapeutics
This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Becca Senter, and it lists only the talks, sessions and presentations named in those programmes.
Is this you? Claim this profile — every request is read by a person before anything is linked.
To ask for a correction or for this profile to be removed, email [email protected].